Morgan Stanley analyst Mark Purcell raised the firm’s price target on Novartis to CHF 91 from CHF 88 and keeps an Underweight rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- Novartis price target raised to CHF 85 from CHF 80 at Barclays
- Pharming Novartis announces first commercial shipments of Joenja in U.S.
- TD Cowen pharmaceuticals analysts to hold analyst/industry conference call
- Novartis’ Sandoz announces EC approval for HCF Hyrimoz
- Novartis’ Entresto receives positive CHMP opinion for pediatric heart failure